NCT00767624

Brief Summary

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Dec 2008

Longer than P75 for phase_2

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 3, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 7, 2008

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2008

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

December 5, 2016

Completed
Last Updated

December 5, 2016

Status Verified

October 1, 2016

Enrollment Period

6.5 years

First QC Date

October 3, 2008

Results QC Date

August 5, 2016

Last Update Submit

October 10, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percent of Participants With Depression Remission

    Depression remission was defined if both a and b below are satisfied 1. absence of both depressed mood and anhedonia for at least three consecutive weeks 2. no more than two other diagnostic criterion symptoms of depression met for at least three consecutive weeks

    16 weeks

Secondary Outcomes (1)

  • Percentage of Participants in Insomnia Remission

    16 weeks

Study Arms (2)

antidepressant + desensitization

OTHER

Combined antidepressant medication (determined by an algorithm) plus desensitization therapy

Drug: AntidepressantBehavioral: Desensitization Therapy for Insomnia

antidepressant + cognitive behavioral

OTHER

Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy

Drug: AntidepressantBehavioral: Cognitive Behavioral Therapy for Insomnia

Interventions

Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance

antidepressant + cognitive behavioralantidepressant + desensitization
antidepressant + desensitization
antidepressant + cognitive behavioral

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Meets criteria for Major Depressive Disorder
  • Between 18 and 75 years of age and adequately fluent in English
  • Meets criteria for an insomnia disorder

You may not qualify if:

  • Women who are currently pregnant, breast-feeding, or not using a reliable birth control method.
  • People for whom the antidepressant medication(s) provided in the study is not indicated
  • People who have had minimum adequate trials of (or have not been able to tolerate) all three study medications.
  • People with uncontrolled medical conditions.
  • People with moderate or severe sleep disorders other than insomnia
  • Individuals on a fixed night shift or rotating work schedule that requires a night shift.
  • Patients with a current principal diagnosis of a psychiatric disorder that necessitates treatment that is not offered in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Stanford University School of Medicine

Stanford, California, 94305, United States

Location

Duke University

Durham, North Carolina, United States

Location

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Location

Related Publications (5)

  • Spina MA, Bei B, Rajaratnam SW, Krystal A, Edinger JD, Buysse DJ, Thase M, Manber R. Cognitive behavioural therapy for insomnia reduces actigraphy and diary measured sleep discrepancy for individuals with comorbid insomnia and major depressive disorder: A report from the TRIAD study. Sleep Med. 2024 Feb;114:137-144. doi: 10.1016/j.sleep.2023.12.014. Epub 2023 Dec 24.

  • Edinger JD, Smith ED, Buysse DJ, Thase M, Krystal AD, Wiskniewski S, Manber R. Objective sleep duration and response to combined pharmacotherapy and cognitive behavioral insomnia therapy among patients with comorbid depression and insomnia: a report from the TRIAD study. J Clin Sleep Med. 2023 Jun 1;19(6):1111-1120. doi: 10.5664/jcsm.10514.

  • Asarnow LD, Bei B, Krystal A, Buysse DJ, Thase ME, Edinger JD, Manber R. Circadian Preference as a Moderator of Depression Outcome Following Cognitive Behavioral Therapy for Insomnia Plus Antidepressant Medications: A Report From the TRIAD Study. J Clin Sleep Med. 2019 Apr 15;15(4):573-580. doi: 10.5664/jcsm.7716.

  • Bei B, Asarnow LD, Krystal A, Edinger JD, Buysse DJ, Manber R. Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. J Consult Clin Psychol. 2018 Mar;86(3):282-293. doi: 10.1037/ccp0000282.

  • Manber R, Buysse DJ, Edinger J, Krystal A, Luther JF, Wisniewski SR, Trockel M, Kraemer HC, Thase ME. Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial. J Clin Psychiatry. 2016 Oct;77(10):e1316-e1323. doi: 10.4088/JCP.15m10244.

MeSH Terms

Conditions

Sleep Initiation and Maintenance DisordersDepression

Interventions

Antidepressive AgentsDesensitization, PsychologicCognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental DisordersBehavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

Psychotropic DrugsCentral Nervous System AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Limitations and Caveats

Our results do not inform clinical guidelines for any single antidepressant medication.

Results Point of Contact

Title
Rachel Manber, PhD
Organization
STANFORD UNIVERSITY

Study Officials

  • Rachel Manber

    Stanford University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 3, 2008

First Posted

October 7, 2008

Study Start

December 1, 2008

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

December 5, 2016

Results First Posted

December 5, 2016

Record last verified: 2016-10

Data Sharing

IPD Sharing
Will not share

Locations